Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.39 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.38 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | ACACB | O00763 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.31 |
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.31 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.31 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21856275 | 1.00 | CYP3A4 (0.39) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24151881 | 0.94 | CYP3A4 (0.42) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24152603 | 0.91 | CYP3A4 (0.36) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24151046 | 0.90 | CYP3A4 (0.40) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24152339 | 0.89 | CYP3A4 (0.40) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL28775247 | 0.88 | CYP3A4 (0.42) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL23902147 | 0.88 | CYP3A4 (0.43) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24151004 | 0.87 | CYP3A4 (0.39) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24151083 | 0.87 | CYP3A4 (0.39) | CYP3A4TSHRATMTDP1ALDH1A1 | |
| SCHEMBL24152335 | 0.86 | CYP3A4 (0.39) | CYP3A4TSHRATMTDP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2025-02-27 | — | — | US | disclosed |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | ARRAY BIOPHARMA INC. (US) | 2025-01-07 | — | — | US | disclosed |
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-07-06 | — | — | US | disclosed |
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| CN-114341124-A | Protein tyrosine phosphatase inhibitors | ARRAY生物制药公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021259077-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2021-12-30 | — | — | WO | disclosed |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2021-12-09 | — | — | US | disclosed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212180-A1 | SUBSTITUTED PYRAZINE COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND USE THEREOF | PTPN5, PTPN1, PTPN2 | CYP3A4 1490/4885TSHR 2812/4885ATM 1279/4885 |
| US-20250066357-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PPM1F, PPP5C | CYP3A4 3857/4885TSHR 3230/4885ATM 917/4885 |
| US-12187721-B2 | Protein tyrosine phosphatase inhibitors | PPM1A, PTP4A1, PPP5C | CYP3A4 3731/4885TSHR 3250/4885ATM 932/4885 |
| US-20210380582-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | PPM1A, PTP4A1, PPP5C | CYP3A4 3731/4885TSHR 3250/4885ATM 932/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.